MedTrace Logo

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

NCT00704847 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1030

Last updated 2019-04-24

Study results available
· View outcomes & findings →

Summary

The purpose of this phase III study is to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Patients with Osteoarthritis of the Knee

Conditions

Interventions

DRUG

Oral Salmon Calcitonin

0.8mg SMC021, twice daily

DRUG

Oral Salmon Calcitonin (Placebo)

0.8mg Placebo, twice daily

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Nordic Bioscience A/S

    lead INDUSTRY

Principal Investigators

  • Bente Juel Riis, MD · Nordic Bioscience

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
51 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2011-05-31
Completion
2011-06-30

Countries

  • United States
  • Belgium
  • Canada
  • Czechia
  • Denmark
  • Hong Kong
  • Poland
  • Romania
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00704847 on ClinicalTrials.gov